Every Form 4 that Annovis Bio, Inc. (ANVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANVS filings page.
Annovis Bio director Michael B. Hoffman reported new open-market purchases of company stock. On May 20, 2026, he bought a total of 76,344 shares of Annovis Bio common stock in three open-market transactions at prices between $1.75 and $1.8999 per share.
Following these transactions, Hoffman directly holds 3,364,883 shares of common stock. A separate entry also reports 223,357 shares held indirectly through The 2024 Hoffman Family Trust, over which he has voting and investment power according to the filing footnote.
Annovis Bio director Michael B. Hoffman made a large open-market purchase of the company’s common stock. On April 2, 2026, he bought 713,800 shares at $2.10 per share, increasing his direct holdings to 3,288,539 shares.
He also has indirect ownership of 223,357 shares held by The 2024 Hoffman Family Trust, over which he has both voting and investment power. The filing shows no derivative securities remaining, so this activity reflects a direct cash investment rather than an options exercise.
Annovis Bio, Inc. director reported open-market purchases of the company’s common stock. On 12/08/2025, the reporting person bought 30,000 shares at $4.3398 per share and an additional 15,000 shares at $4.24 per share. After these transactions, the reporting person beneficially owned 2,574,739 shares of Annovis Bio common stock directly. An additional 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.
Annovis Bio, Inc. (ANVS) reported an amended Form 4 for a director showing multiple open-market purchases of common stock on 11/24/2025. The director bought 1,489 shares at $4.13, 9,200 shares at $3.85, 415 shares at $4.14, and 28,096 shares at $4.15. After these transactions, the director beneficially owned 2,529,739 shares directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The amendment states it was filed to correct the share totals shown in column 5 after each reported transaction, with no other changes to the previously reported trades.
A director of Annovis Bio, Inc. (ANVS) reported several open-market purchases of the company’s common stock. On 11/24/2025, the director bought blocks of Annovis Bio common shares at prices of $4.13, $3.85, $4.14, and $4.15 per share, each coded as a purchase transaction.
Following these transactions, the director beneficially owns 2,519,739 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power. The filing confirms the director’s status and that the report is filed for a single reporting person.
Annovis Bio, Inc. (ANVS) reported an insider stock purchase by a director. On 11/21/2025, the reporting person bought 10,000 shares of common stock at $3.49 per share and another 10,000 shares at $3.50 per share. After these transactions, the director beneficially owned 2,490,539 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.
Annovis Bio, Inc. director reported purchasing 15,000 shares of common stock at $2.11 per share on 11/14/2025.
After this transaction, the director beneficially owns 2,470,539 shares directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.
Annovis Bio (ANVS) reported an insider share purchase by President & CEO and Director Maria Maccecchini. On 10/28/2025, she acquired 97,561 shares of common stock at $2.05 per share.
Following the transaction, she beneficially owns 1,212,020 shares, held directly. This filing reflects a personal share acquisition by a senior executive.
Annovis Bio (ANVS) — insider transaction. A director reported purchasing 975,610 shares of common stock at $2.05 on 10/28/2025 (Transaction Code P). Following the trade, the filer reported 2,455,539 shares held directly and 223,357 shares held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The filing notes the reporting person has voting and investment power over the trust-held shares.
Annovis Bio (ANVS) reported an insider transaction on a Form 4. Director Claudine Bruck exercised a stock option and acquired 7,142 shares of common stock at $0.14 per share on 09/10/2025 (transaction code M).
Following the transaction, her directly held common stock totaled 13,709 shares. The option exercised had been exercisable since 09/18/2016 and carried an expiration date of 09/18/2025, and the derivative position reported after the exercise was 0.